Cost and Care of Patients with Alzheimer’s Disease: Clinical Predictors in German Health Care Settings

Manuscript Number: 

11-0539R1

Author(s): 
Erika Baum, Frank Dannhoff, Richard Dodel, Monika-Balzer Geldsetzer, Dajana Henkel, Philipp Hessmann, Pamela Hirzmann, Frank Jessen, Matthias J. Muller, Jens Peter Reese, Jurgen Rieke, Greta Seeberg

Disclosures

Erika Baum

  • Nothing to Disclose

Frank Dannhoff

  • Nothing to Disclose

Richard Dodel

  • Consulting Fees:
    Lilly, Octapharma, GE Healthcare, Baxter, Rentschler
    Lecture Fees:
    Novartis, Merz, Solvay, Eisai, Lundbeck, Orion Pharma, UCB, Pfizer, CSL Behring, Octapharma, Teva Pharma, Affiris
    Patents/Royalties
    Patents
    Grants
    • Agency: 
      Lundbeck
      Dates: 
      2011

Monika-Balzer Geldsetzer

  • Nothing to Disclose

Dajana Henkel

  • Nothing to Disclose

Philipp Hessmann

  • Nothing to Disclose

Pamela Hirzmann

  • Lecture Fees:
    AstraZeneca, Eisai, Lundbeck, Merz, Novartis

Frank Jessen

  • Nothing to Disclose

Matthias J. Muller

  • Nothing to Disclose

Jens Peter Reese

  • Consulting Fees:
    Dr. Reese received consulting fees from Lundbeck.
    Lecture Fees:
    Dr. Reese received lecture fees from Abbott, Lundbeck and TEVA.

Jurgen Rieke

  • Lecture Fees:
    AstraZeneca, Eisai, Lundbeck, Merz und Novartis

Greta Seeberg

  • Nothing to Disclose